Clinical Classification of Rare Cardiovascular Diseases and Disorders: 2018 Update


Full Text:

PDF

Abstract


Rare diseases and disorders constitute important clinical problems. There are many concerns among physicians while planning the diagnostic and treatment process of such a heterogenous group of patients. These concerns arise not only from the rarity of cases, but also from multiple gaps in knowledge on the management of patients with rare diseases and disorders. The commonly accepted prevalence of rare diseases and disorders is 1 per 2 000 in the general population or less. Incidental prevalence and multiplicity of comorbidities result in an inability to gather enough experience at any single centre. Thus, cooperation and the exchange of ideas is important for the management of patients with rare diseases. Classification of rare cardiovascular diseases and disorders (RCDD) is crucial for expanding knowledge in the field of RCDD. It consists of an overview of RCDD, facilitates clinical approaches to patients and makes the creation of registries and databases easier. We hope that the updated RCDD classification will aid medical practice through the contribution to progress in diagnostics and therapy. It also serves as a summary of scientific achievements in the field of RCDD. Without the grouping of specific disorders, it is very difficult to create diagnostic and therapeutic algorithms. The Classification of RCDD was published for the first time in the Journal of Rare Cardiovascular Diseases (JRCD) in 2013 [1]. RCDD classification was discussed during the 2013 European Society of Cardiology Congress held in Amsterdam (www.crcd.eu/?p=2800) and in international journals, including a recent publication of the European Heart Journal [2, 3]. Clinical classification of RCDD takes into account major clinical symptoms and pathologies and is based on common clinical and/or anatomical features.

Keywords


Classification; Rare; Cardiovascular Disease; Cardiovascular Disorder

References


Podolec P. Classification of Rare Cardiovascular Diseases (RCD Classification), Krakow 2013. J Rare Cardiovasc Dis 2013; 1 (2): 49–60.

Podolec P. Rare cardiovascular diseases. Eur Heart J 2017; 38: 3190-3192.

Podolec P, Stepniewski J, Podolec J, et al. Rare cardiovascular diseases: from European legislations to classification and clinical practice. Kardiol Pol 2015; 73: 135-141.

https://www.orpha.net/consor/cgi-bin/index.php?lng=EN

List of rare diseases and synonyms listed in alphabetical order, Orphanet Report Series, Rare Diseases collection, June 2017, http://www.orpha.net/orphacom/cahiers/docs/GB/List_of_rare_diseases_in_alphabetical_order.pdf.

https://www.orpha.net/orphacom/cahiers/docs/GB/eproc_disease_inventory_PR_R1_Nom_04.pdf

Ayme S, Bellet B, Rath A. Rare diseases in ICD11: making rare diseases visible in health information systems through appropriate coding. Orphanet J Rare Dis 2015; 10: 35.

http://www.who.int/classifications/icd/revision/betaexpectations/en/

Matusik PT. Insights into channelopathies: progress in clinical practice and research. J Electrocardiol 2017; 50: 534-535.

Decision No 1295/1999/EC of the European Parliament and of the Council of 29 April 1999 adopting a programme of Community action on rare diseases within the framework for action in the field of public health (1999 to 2003). Official Journal of the European Union 1999; L 155: 1–6.

International Statistical Classification of Diseases and Related Health Problems 10th Revision. Accessed at: http://apps.who.int/classifications/icd10/browse/2016/en.

Podolec P, Matusik PT. Clinical classification of rare cardiovascular diseases and disorders: upcoming 2018 update. J Rare Cardiovasc Dis 2017; 3: 14–15.

Alpers BJ, Berry RG, Paddison RM. Anatomical studies of the circle of Willis in normal brain. AMA Arch Neurol Psychiatry 1959; 81: 409-418.

Kau T, Sinzig M, Gasser J, et al. Aortic development and anomalies. Semin Intervent Radiol 2007; 24: 141-152.

Hastreiter AR, D'Cruz IA, Cantez T, et al. Right-sided aorta. I. Occurrence of right aortic arch in various types of congenital heart disease. II. Right aortic arch, right descending aorta, and associated anomalies. Br Heart J 1966; 28: 722-739.

Angelini P, Velasco JA, Flamm S. Coronary anomalies: incidence, pathophysiology, and clinical relevance. Circulation 2002; 105: 2449-2454.

Klapkowski A, Siondalski P, Duda M, et al. Bland-White-Garland syndrome in a 39-year-old lumberjack. Kardiol Pol 2018; 76: 1114.

Hussain B, Sultan FAT, Jamil Z. The prevalence of coronary artery anomalies on CT scan – experience from a tertiary care center in Pakistan (RCD code: I‑1C.1). J Rare Cardiovasc Dis 2017; 3 (4): 116–121.

Beridze N, Frishman WH. Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis, and prevention and treatment of its complications. Cardiol Rev 2012; 20: 4-7.

Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005; 37: 275-281.

Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation 2005; 111: 816-828.

Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010; 121: e266-369.

Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33: 1129-1134.

Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990; 33: 1135-1136.

Basu N, Watts R, Bajema I, et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 2010; 69: 1744-1750.

Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010; 69: 798-806.

Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008; 67: 1004-1010.

Plouin PF, Perdu J, La Batide-Alanore A, et al. Fibromuscular dysplasia. Orphanet J Rare Dis 2007; 2: 28.

Baumgartner RW, Arnold M, Baumgartner I, et al. Carotid dissection with and without ischemic events: local symptoms and cerebral artery findings. Neurology 2001; 57: 827-832.

Chlebus K, Cybulska B, Gruchala M, et al. Prevalence, diagnosis, and treatment of familial hypercholesterolaemia in outpatient practices in Poland. Kardiol Pol 2018; 76: 960-967.

Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.

Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D34-41.

Kopec G, Stepniewski J, Waligora M, et al. Staged treatment of central and peripheral lesions in chronic thromboembolic pulmonary hypertension. Pol Arch Med Wewn 2016; 126: 97-99.

Marelli AJ, Mackie AS, Ionescu-Ittu R, et al. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007; 115: 163-172.

Duffels MG, Engelfriet PM, Berger RM, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol 2007; 120: 198-204.

Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008; 32: 1371-1385.

Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global

perspective. Chest 2010; 137: 39S-51S.

Rubiś P, Wiśniowska‑Śmiałek S, Tomkiewicz‑Pająk L, et al. Severe course of dilated cardiomyopathy associated with Duchenne muscular dystrophy (RCD code: III‑1A.3a). J Rare Cardiovasc Dis 2014; 2 (1): 18–22.

Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29: 270-276.

Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113: 1807-1816.

Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003; 24: 1965-1991.

Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: 2761-2796.

Authors/Task Force m, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733-2779.

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-2200.

Houyel L, Khoshnood B, Anderson RH, et al. Population-based evaluation of a suggested anatomic and clinical classification of congenital heart defects based on the International Paediatric and Congenital Cardiac Code. Orphanet J Rare Dis 2011; 6: 64.

Mavroudis C, Jacobs JP. Congenital Heart Surgery Nomenclature and Database Project: overview and minimum dataset. Ann Thorac Surg 2000; 69: S2-17.

Lacour-Gayet F, Maruszewski B, Mavroudis C, et al. Presentation of the International Nomenclature for Congenital Heart Surgery. The long way from nomenclature to collection of validated data at the EACTS. Eur J Cardiothorac Surg 2000; 18: 128-135.

Maruszewski B, Lacour-Gayet F, Elliott MJ, et al. Congenital Heart Surgery Nomenclature and Database Project: update and proposed data harvest. Eur J Cardiothorac Surg 2002; 21: 47-49.

Gaynor JW, Jacobs JP, Jacobs ML, et al. Congenital Heart Surgery Nomenclature and Database Project: update and proposed data harvest. Ann Thorac Surg 2002; 73: 1016-1018.

Thiene G, Frescura C. Anatomical and pathophysiological classification of congenital heart disease. Cardiovasc Pathol 2010; 19: 259-274.

Morales-Demori R. Congenital heart disease and cardiac procedural outcomes in patients with trisomy 21 and Turner syndrome. Congenit Heart Dis 2017; 12: 820-827.

Martin T, Smith A, Breatnach CR, et al. Infants Born with Down Syndrome: Burden of Disease in the Early Neonatal Period. J Pediatr 2018; 193: 21-26.

Franklin RC, Jacobs JP, Krogmann ON, et al. Nomenclature for congenital and paediatric cardiac disease: historical perspectives and The International Pediatric and Congenital Cardiac Code. Cardiol Young 2008; 18 Suppl 2: 70-80.

Bergersen L, Everett AD, Giroud JM, et al. Report from The International Society for Nomenclature of Paediatric and Congenital Heart Disease: cardiovascular catheterisation for congenital and paediatric cardiac disease (Part 1 - Procedural nomenclature). Cardiol Young 2011; 21: 252-259.

Bergersen L, Giroud JM, Jacobs JP, et al. Report from The International Society for Nomenclature of Paediatric and Congenital Heart Disease: cardiovascular catheterisation for congenital and paediatric cardiac disease (Part 2 - Nomenclature of complications associated with interventional cardiology). Cardiol Young 2011; 21: 260-265.

Komar M. Cardiac Tumours and Malignancy Diseases. J Rare Cardiovasc Dis 2018; 3 (6): 190–192.

Reynen K. Frequency of primary tumors of the heart. Am J Cardiol 1996; 77: 107.

Lee E, Mahani MG, Lu JC, et al. Primary cardiac tumors associated with genetic syndromes: a comprehensive review. Pediatr Radiol 2018; 48: 156-164.

Burazor I, Aviel-Ronen S, Imazio M, et al. Metastatic cardiac tumors: from clinical presentation through diagnosis to treatment. BMC Cancer 2018; 18: 202.

Gąsior Z, Mizia‑Stec K, Kasztelan‑Masłowska M. Metastatic tumor of the left atrium (RCD code: VI‑2O). J Rare Cardiovasc Dis 2016; 2 (6): 189–191.

Matusik PT, Pudło J, Rydlewska A, et al. Brugada syndrome: current diagnostics, epidemiology, genetic data and novel mechanisms (RCD code: V-1A.1). J Rare Cardiovasc Dis 2017; 3 (3): 73-80.

Matusik PT, Komar M, Podolec J, et al. Exercise ECG unmasked Brugada sign: manifestation of the risk of sports-associated sudden cardiac arrest (RCD code: V-1A.1). J Rare Cardiovasc Dis 2017; 3 (3): 92–97.

Casado-Arroyo R, Berne P, Rao JY, et al. Long-Term Trends in Newly Diagnosed Brugada Syndrome: Implications for Risk Stratification. J Am Coll Cardiol 2016; 68: 614-623.

Rohatgi RK, Sugrue A, Bos JM, et al. Contemporary Outcomes in Patients With Long QT Syndrome. J Am Coll Cardiol 2017; 70: 453-462.

Mazzanti A, Underwood K, Nevelev D, et al. The new kids on the block of arrhythmogenic disorders: Short QT syndrome and early repolarization. J Cardiovasc Electrophysiol 2017; 28: 1226-1236.

Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol 2014; 63: 1300-1308.

Lieve KV, van der Werf C, Wilde AA. Catecholaminergic Polymorphic Ventricular Tachycardia. Circ J 2016; 80: 1285-1291.

Matusik PT, Rydlewska A, Pudło J, et al. Brugada syndrome: new concepts and algorithms in management (RCD code: V-1A.1). J Rare Cardiovasc Dis 2017; 3 (5): 151-160.

Bordachar P, Zachary W, Ploux S, et al. Pathophysiology, clinical course, and management of congenital complete atrioventricular block. Heart Rhythm 2013; 10: 760-766.

Nagaoka I, Matsui K, Ueyama T, et al. Novel mutation of plakophilin-2 associated with arrhythmogenic right

ventricular cardiomyopathy. Circ J 2006; 70: 933-935.

Bradfield JS, Shivkumar K. Cardiac resynchronization therapy-induced proarrhythmia: understanding preferential conduction within myocardial scars. Circ Arrhythm Electrophysiol 2014; 7: 1000-1002.

Schwerg M, Baldenhofer G, Dreger H, et al. Complete atrioventricular block after TAVI: when is pacemaker implantation safe? Pacing Clin Electrophysiol 2013; 36: 898-903.

Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013; 34: 2281-2329.

Fuest S, Gleva MJ, Noheria A. Regular tachycardia despite Wenckebach atrioventricular conduction. J Electrocardiol 2018; 51: 126-128.

El-Assaad I, Al-Kindi SG, Oliveira GH, et al. Pacemaker implantation in pediatric heart transplant recipients: Predictors, outcomes, and impact on survival. Heart Rhythm 2015; 12: 1776-1781.

Hindricks G. Incidence of complete atrioventricular block following attempted radiofrequency catheter modification of the atrioventricular node in 880 patients. Results of the Multicenter European Radiofrequency Survey (MERFS) The Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 1996; 17: 82-88.

Klapkowski A, Pawlaczyk R, Kempa M, et al. Complete atrioventricular block after isolated aortic valve replacement. Kardiol Pol 2016; 74: 985-993.

Camm AJ. Hopes and disappointments with antiarrhythmic drugs. Int J Cardiol 2017; 237: 71-74.

Glover BM, Baranchuk A. Amiodarone for atrial fibrillation: Friend or foe? Cardiol J 2015; 22: 603-604.

Acunzo RS, Tepper RB, Moulson N, et al. Ictal asystole: an opportunity for pacing. Kardiol Pol 2016; 74: 598.

Matusik PT, Zabek A, Matusik PS, et al. Atrioventricular synchrony in the background of ventricular noise and undersensing. Ann Noninvasive Electrocardiol 2017; 22.

Heidbuchel H, Prior DL, La Gerche A. Ventricular arrhythmias associated with long-term endurance sports: what is the evidence? Br J Sports Med 2012; 46 Suppl 1: i44-50.

Younes A, Al-Kindi SG, Alajaji W, et al. Presence of Implantable Cardioverter-Defibrillators and Wait-List Mortality of Patients Supported with Left Ventricular Assist Devices as Bridge to Heart Transplantation. Int J Cardiol 2017; 231: 211-215.

Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J 2011; 32: 3147-3197.

Siu SC, Colman JM. Heart disease and pregnancy. Heart 2001; 85: 710-715.

Leśniak‑Sobelga A, Tomkiewicz‑Pająk L, Pająk J, Podolec P. Pregnant woman with Ebstein’s anomaly. J Rare

Cardiovasc Dis 2012; 1 (1): 13–17.

Ząbek A, Małecka B, Matusik PT et al. Pregnancy and congenital complete atrioventricular block: management during pregnancy and the periparturient period (RCD code: VII‑V). J Rare Cardiovasc Dis 2018; 3 (6): 204–208.

Hussain B, Sultan FAT. A rare cardiac manifestation of Brucellosis (RCD code: VIII). J Rare Cardiovasc Dis 2017; 3 (4): 129–132.

Matusik P, Tomaszewski K, Chmielowska K, et al. Severe frailty and cognitive impairment are related to higher mortality in 12-month follow-up of nursing home residents. Arch Gerontol Geriatr 2012; 55: 22-24.

Michalik C, Matusik P, Nowak J, et al. Heart failure, comorbidities, and polypharmacy among elderly nursing home residents. Pol Arch Med Wewn 2013; 123: 170-175.

Tomkiewicz-Pająk L. Common problems in rare congenital heart diseases. J Rare Cardiovasc Dis 2017; 3 (5): 149–150.

Vigl M, Niggemeyer E, Hager A, et al. The importance of socio-demographic factors for the quality of life of adults with congenital heart disease. Qual Life Res 2011; 20: 169-177.




DOI: http://dx.doi.org/10.20418%2Fjrcd.vol3no7.330

Refbacks

  • There are currently no refbacks.
Journal of Rare Cardiovascular Diseases (JRCD)
John Paul II Hospital in Kraków, 80 Prądnicka Str., 31-202 Kraków, Poland
Phone: +48 (12) 614 33 99, +48 (12) 614 34 88 Fax: +48 (12) 614 34 88
e-mail: rarediseases@szpitaljp2.krakow.pl
Published by SoftQ sp. z o.o.
ul. Oleandry 2, 30-063 Kraków, Poland
Phone: +48 (12) 444 1650 Fax: +48 (12) 444 1659
e-mail: softq@softq.pl